INGELHEIM, Germany — (BUSINESS WIRE) — Boehringer Ingelheim have announced the results of a subgroup analysis of the CARMELINA® trial which demonstrate that linagliptin did not increa…
CARMELINA® subgroup analysis supports long-term cardiovascular and renal safety of linagliptin in older people with type 2 diabetes
INGELHEIM, Germany — (BUSINESS WIRE) — Boehringer Ingelheim have announced the results of a subgroup analysis of the CARMELINA® trial which demonstrate that linagliptin did not increa…